OOIR: Observatory of International Research

Papers

(The H4-Index of Alimentary Pharmacology & Therapeutics is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)

Article	Citations
Review article: gastrointestinal features in COVID‐19 and the possibility of faecal transmission	610
Systematic review with meta‐analysis: liver manifestations and outcomes in COVID‐19	180
Editorial: low population mortality from COVID‐19 in countries south of latitude 35 degrees North supports vitamin D as a factor determining severity	172
2019 novel coronavirus disease (COVID‐19) in patients with inflammatory bowel diseases	142
Review article: COVID‐19 and liver disease—what we know on 1st May 2020	127
Letter: Covid‐19, and vitamin D	112
Systematic review with meta‐analysis: SARS‐CoV‐2 stool testing and the potential for faecal‐oral transmission	103
Review article: the emerging role of genetics in precision medicine for patients with non‐alcoholic steatohepatitis	100
Nonalcoholic fatty liver disease progression rates to cirrhosis and progression of cirrhosis to decompensation and mortality: a real world analysis of Medicare data	99
Long‐term safety of vedolizumab for inflammatory bowel disease	91
Modelling NAFLD disease burden in four Asian regions—2019‐2030	89
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatment	87
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world	83
Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease	83
Review article: prevention, diagnosis and management of COVID‐19 in the IBD patient	83
The effectiveness of either ustekinumab or vedolizumab in 239 patients with Crohn's disease refractory to anti‐tumour necrosis factor	78
Systematic review: the global incidence of faecal microbiota transplantation‐related adverse events from 2000 to 2020	77
Review article: FODMAPS, prebiotics and gut health‐the FODMAP hypothesis revisited	75
Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging	75
Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn’s disease	74
Safety and efficacy of tofacitinib for treatment of ulcerative colitis: final analysis of OCTAVE Open, an open‐label, long‐term extension study with up to 7.0 years of treatment	68
Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry	67
Liver involvement is not associated with mortality: results from a large cohort of SARS‐CoV‐2‐positive patients	67
Randomised clinical trial: faecal microbiota transplantation versus autologous placebo administered via colonoscopy in irritable bowel syndrome	66
Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices	62

Systematic review: radiomics for the diagnosis and prognosis of hepatocellular carcinoma	62
Tofacitinib for ulcerative colitis: results of the prospective Dutch Initiative on Crohn and Colitis (ICC) registry	59
Gastric mucosal microbiota in a Mongolian population with gastric cancer and precursor conditions	58
Systematic review with meta‐analysis: comparative risk of lymphoma with anti‐tumour necrosis factor agents and/or thiopurines in patients with inflammatory bowel disease	55
Systematic review and meta‐analysis: efficacy and safety of early biologic treatment in adult and paediatric patients with Crohn’s disease	54
A disease‐specific decline of the relative abundance of Bifidobacterium in patients with autoimmune hepatitis	52
Changing patterns in the epidemiology and outcomes of inflammatory bowel disease in the United Kingdom: 2000‐2018	50
Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard‐dose subcutaneous maintenance therapy	50
Systematic review and network meta‐analysis: efficacy of drugs for functional dyspepsia	50
Systematic review with network meta‐analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH	49
Randomised clinical trial: standard of care versus early‐transjugular intrahepatic porto‐systemic shunt (TIPSS) in patients with cirrhosis and oesophageal variceal bleeding	49
Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real‐world cohort study	49
Faecal immunochemical testing for adults with symptoms of colorectal cancer attending English primary care: a retrospective cohort study of 14 487 consecutive test requests	49
Transperineal ultrasound predicts endoscopic and histological healing in ulcerative colitis	49
Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients	49
Systematic review with meta‐analysis: biologics and risk of infection or cancer in elderly patients with inflammatory bowel disease	48
Review article: therapeutic aspects of bile acid signalling in the gut‐liver axis	48
Improvement in histological endpoints of MAFLD following a 12‐week aerobic exercise intervention	46
Analysis of 61 exclusive enteral nutrition formulas used in the management of active Crohn’s disease—new insights into dietary disease triggers	45
Pregnancy outcomes in women with inflammatory bowel disease: a 10‐year nationwide population‐based cohort study	45